Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 8, 2002
Last updated: February 19, 2010
Last verified: November 2008

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given with combination chemotherapy and to see how well they work in treating patients with non-small cell lung cancer that cannot be surgically removed.

Condition Intervention Phase
Lung Cancer
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Maximum tolerated dose (MTD) as assessed by dose-limiting toxicity within 1 month after completion of study treatment (phase I) [ Designated as safety issue: Yes ]
  • Survival at 2 years (phase II) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Survival time, time to disease progression, and time to local progression as assessed by clinical measures based on H&P after completion of study treatment [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]

Estimated Enrollment: 90
Study Start Date: May 2002
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated dose of radiotherapy in combination with carboplatin and paclitaxel in patients with unresectable non-small cell lung cancer.
  • Determine the 2-year survival of patients treated with this regimen.
  • Determine the progression-free local control rate in patients treated this regimen.
  • Determine the tolerability of this regimen in these patients.
  • Assess the quality of life of patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of radiotherapy.

Patients undergo radiotherapy* once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continutes in the absence of disease progression or unacceptable toxicity.

NOTE: *No prophylactic nodal radiotherapy is administered

Cohorts of 3-6 patients receive escalating doses of radiotherapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 12 additional patients are treated at that dose level in the phase II portion of the study.

Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.

Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

    • Stage I, II, or III NSCLC that is unresectable due to tumor extent or other medical reasons
  • Measurable disease
  • Tumor must not exceed volume that would require radiation volumes greater than those allowed on this study
  • No more than blunting of the costophrenic angle on chest x-ray due to pleural effusions
  • No more than small effusions seen on chest CT scan only
  • No supraclavicular adenopathy



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • At least 12 weeks


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Total bilirubin no greater than 1.5 times upper limit of normal (ULN) OR
  • Direct bilirubin no greater than 1.5 times ULN
  • AST no greater than 3 times ULN


  • Creatinine clearance at least 40 mL/min


  • No New York Heart Association class III or IV heart disease


  • FEV_1 at least 1 L or 35% of predicted


  • No grade 2 or greater peripheral neuropathy
  • No weight loss of 10% or more within the past 3 months
  • No uncontrolled infection
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinoma (carcinoma in situ), or localized prostate cancer
  • No other severe underlying disease that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception



  • No prior biologic therapy for NSCLC
  • No concurrent biologic therapy
  • No concurrent prophylactic filgrastim (G-CSF)


  • No prior chemotherapy for NSCLC
  • No other concurrent chemotherapy

Endocrine therapy:

  • No prior endocrine therapy for NSCLC


  • No prior radiotherapy for NSCLC


  • No prior surgery for NSCLC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00032032

  Show 51 Study Locations
Sponsors and Collaborators
North Central Cancer Treatment Group
Study Chair: Steven E. Schild, MD Mayo Clinic
  More Information

Additional Information:
Schild S, Graham D, Hillman S, et al.: Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 27 (Suppl 15): A-7544, 2009.
Schild SE, McGinnis WL, Graham D, et al.: Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-73, S44, 2005.

Responsible Party: Charles L. Loprinzi, Mayo Clinic Cancer Center Identifier: NCT00032032     History of Changes
Other Study ID Numbers: CDR0000069250, NCCTG-N0028
Study First Received: March 8, 2002
Last Updated: February 19, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I non-small cell lung cancer
stage II non-small cell lung cancer
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on July 01, 2015